Persistency and Change of the Bone Mineral Density with Alendronate Treatment after Hip Fracture |
Hwang, Kyu-Tae
(Department of Orthopedic Surgery, College of Medicine, Hanyang University)
Yoo, Byeong-Wook (Department of Orthopedic Surgery, College of Medicine, Hanyang University) Kim, Yee-Suk (Department of Orthopedic Surgery, College of Medicine, Hanyang University) Choi, Il-Yong (Department of Orthopedic Surgery, College of Medicine, Hanyang University) Kim, Young-Ho (Department of Orthopedic Surgery, College of Medicine, Hanyang University) |
1 | Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone. 1995;17 Suppl:505-11. |
2 | Reginster JY, Bruyere O, Audran M, et al. Do estrogens effectively prevent osteoporosis-related fractures? The Group for the Respect of Ethics and Excellence in Science. Calcif Tissue Int. 2000;67:191-4. DOI |
3 | Bellantonio S, Fortinsky R, Prestwood K. How well are community-living women treated for osteoporosis after hip fracture? J Am Geriatr Soc. 2001;49:1197-204. DOI ScienceOn |
4 | Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80:856-61. DOI ScienceOn |
5 | Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21:1453-60. DOI ScienceOn |
6 | Lyles KW, Colo'n-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-809. DOI ScienceOn |
7 | Orimo H, Sugioka Y, Fukunaga H, et al. Diagnostic criteria of primary osteoporosis. Osteoporosis Japan. 1996; 4:643- 653. |
8 | Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367:2010-8. DOI ScienceOn |
9 | Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23:570-8. DOI ScienceOn |
10 | Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging. 2000;12:1-12. |
11 | Mounach A, Abayi DA, Ghazi M, et al. Discordance between hip and spine bone mineral density measurement using DXA: prevalence and risk factors. Semin Arthritis Rheum. 2009;38:467-71. DOI ScienceOn |
12 | Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353:878-82. DOI ScienceOn |
13 | Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA. Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int. 2000;11:460-6. DOI ScienceOn |
14 | van Staa TP, Leufkens HG, Cooper C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int. 2002;13:624-9. DOI ScienceOn |
15 | Colon-Emeric C, Kuchibhatla M, Pieper C, et al. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int. 2003;14:879-83. DOI ScienceOn |
16 | Lonnroos E, Kautiainen H, Karppi P, Hartikainen S, Kiviranta I, Sulkava R. Incidence of second hip fractures. A population-based study. Osteoporos Int. 2007;18:1279-85. DOI ScienceOn |
17 | Berry SD, Samelson EJ, Hannan MT, et al. Second hip fracture in older men and women: the Framingham Study. Arch Intern Med. 2007;167:1971-6. DOI ScienceOn |
18 | Rietbrock S, Olson M, van Staa TP. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM. 2009;102:35-42. DOI ScienceOn |
19 | Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am. 2000;82-A:1063-70. |
20 | Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19:811-8. DOI ScienceOn |
21 | Harrington JT, Broy SB, Derosa AM, Licata AA, Shewmon DA. Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Rheum. 2002;47:651-4. DOI ScienceOn |
22 | Heaney RP, Yates AJ, Santora AC 2nd. Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res. 1997;12:1143-51. DOI ScienceOn |
23 | Ravn P, Weiss SR, Rodriguez-Portales JA, et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab. 2000;85:1492-7. DOI ScienceOn |
24 | Chesnut CH 3rd, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporosis woman: effect of multiple dosage on bone mass and bone remodeling. AM J Med. 1995;99:144-52. DOI ScienceOn |
25 | Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006;65:654-61. DOI ScienceOn |
26 | Weinreb M, Rodan GA, Thompson DD. Osteopenia in the immobilized rat hind limb is associated with increased bone resorption and decreased bone formation. Bone. 1989;10:187-94. DOI ScienceOn |
27 | Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189-99. DOI ScienceOn |
28 | Magnusson HI, Linden C, Obrant KJ, Johnell O, Karlsson MK. Bone mass changes in weight-loaded and unloaded skeletal regions following a fracture of the hip. Calcif Tissue Int. 2001;69:78-83. DOI ScienceOn |
29 | van der Poest Clement E, van Engeland M, Ader H, Roos JC, Patka P, Lips P. Alendronate in the prevention of bone loss after a fracture of the lower leg. J Bone Miner Res. 2002;17:2247-55. DOI ScienceOn |
30 | Pocock NA, Eisman JA, Yeates MG, Sambrook PN, Eberl S. Physical fitness is a major determinant of femoral neck and lumbar spine bone mineral density. J Clin Invest. 1986;78:618-21. DOI ScienceOn |
31 | Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Eberl S. Genetic determinants of bone mass in adults. A twin study. J Clin Invest. 1987;80:706-10. DOI ScienceOn |
32 | Cecilia D, Jodar E, Fernandez C, Resines C, Hawkins F. Effect of alendronate in elderly patients after low trauma hip fracture repair. Osteoporos Int. 2009;20:903-10. DOI ScienceOn |
33 | Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med. 2006;119 Suppl:12-7. |
34 | Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003;14:259-62. |
35 | Hans D, Downs RW Jr, Duboeuf F, et al. Skeletal sites for osteoporosis diagnosis: the 2005 ISCD Official Positions. J Clin Densitom. 2006;9:15-21. DOI ScienceOn |